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Highly homogeneous antibody modiﬁcation
through optimisation of the synthesis and
conjugation of functionalised
dibromopyridazinediones†
Calise Bahou,‡a Daniel A. Richards, ‡a Antoine Maruani, a Elizabeth A. Love, b
Faiza Javaid,a Stephen Caddick,a James R. Baker *a and Vijay Chudasama *a,c
Due to their exquisite cysteine-selectivity, excellent stability, and ability to functionally rebridge disulﬁde
bonds, dibromopyridazinediones are emerging as an exciting new class of bioconjugation reagents, par-
ticularly in the ﬁeld of antibody conjugation. Despite this, relatively little work has been performed on the
optimisation of their synthesis and subsequent reaction with immunoglobulins. Herein we present a novel
synthetic route towards functionalised dibromopyridazinediones, proceeding via an isolatable dibromo-
pyridazinedione-NHS ester. Reaction of this activated intermediate with a variety of amines produces
functional dibromopyridazinediones in good to excellent yields. The disulﬁde rebridging capacity of these
reagents was optimised on the clinically relevant IgG1 trastuzumab, resulting in a general method which
allows for the generation of site-selectively modiﬁed native trastuzumab with over 90% homogeneity (no
disulﬁde scrambling) without the need for protein engineering or enzymatic conjugation.
Introduction
Over the last few decades biologists, biochemists, and chemi-
cal biologists have put forth a concerted eﬀort to explore and
harness the unique attributes of antibodies, particularly their
exquisite targeting specificity, excellent in vivo stability, and
ability to initiate antibody-dependent cell-mediated cyto-
toxicity (ADCC).1 These properties make antibodies excellent
biomolecules for a plethora of tasks, especially as therapeutic
agents. Their therapeutic utility has been bolstered by
advancements in hybridoma and phage display technology,
which enable the rapid generation of high-aﬃnity monoclonal
antibodies against emerging diseases.2,3 Despite the many
advantages of antibodies, their chemical functionality is
limited to the reactivities of the 20 natural amino acids. To
fully exploit antibodies for biomedical applications it is desir-
able to expand their reactivity beyond the capacity of the
natural amino acids. To this end, significant research eﬀort
has been devoted to developing new methods for functionalis-
ing antibody scaﬀolds through chemical conjugation.4–7 The
chemical modification of antibodies has led to the develop-
ment of a novel class of biologics; antibody–drug conjugates
(ADCs).8
Despite their utility, many conjugation strategies for synthe-
sising ADCs suﬀer from several drawbacks. The targeting of
amino acids frequently provides no regioselectivity over the
modification when trying to aim for drug loadings of 2–4
(commonly tolerated drug loadings in terms of pharmaco-
kinetics), leading to heterogeneous product mixtures. This is
particularly true when targeting lysine residues, which are
highly abundant on the solvent accessible surface of anti-
bodies.8 Despite this, lysine conjugation is employed for
the generation of clinically approved ADCs Kadcyla® and
Besponsa®.9,10 To overcome the issue of lysine over-abun-
dance, cysteine-selective reagents are frequently employed.
Although native antibodies contain no solvent accessible reac-
tive cysteine residues, liberation of cysteine residues from
reduction of the inter-chain disulfide bonds provides suitable
targets. Unfortunately, this reduction results in a loss of the
stabilising disulfide bridges and, in the instance of IgG1 anti-
bodies, generates up to 8 reactive cysteine residues – factors
which can contribute to heterogeneity when targeting typically
tolerated loadings of 2–4 drugs per antibody.8 Conjugation to
liberated cysteine residues was employed for the generation of
the ADC Adcetris®.11 The issues of uncontrolled conjugation
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are particularly problematic for therapeutic applications,
where suboptimal drug loading can lead to poor pharmaco-
kinetic properties and a narrow therapeutic window.12 As
such, research focus has shifted to developing technologies
which allow for site-specific conjugation. This is commonly
achieved using protein engineering to install a site-specific
cysteine residue or unnatural amino acid, or through enzy-
matic processes.8 Whilst these methods work well, their acces-
sibility is limited as the process must be optimised for each
individual antibody; a time-consuming and expensive process.
One promising alternative approach utilises reagents that
are capable of functionally rebridging the cysteine residues lib-
erated from reduction of the disulfide bonds of native anti-
bodies. This provides site-selectivity, a generally tolerated drug
loading of 4 (as IgG1s contain only 4 solvent accessible di-
sulfide bonds), and allows for retention of the covalent stabi-
lising bridge. The most commonly employed disulfide brid-
ging reagents include next-generation maleimides and bis-
sulfones.13–21 Whilst these reagents represent important steps
towards developing homogeneous antibody constructs without
the need for protein engineering, improvements are still
needed. For example, using reagents that show: (i) no (or at
least minimal) cross-reactivity with common reducing agents;
(ii) do not require a hydrolysis step to confer serum stability;
and/or (iii) do not aﬀord appreciable amounts of incorrectly
functionally rebridged species such as half antibody (HL) con-
jugates (see Fig. 1).13,15
Most recently, dibromopyridazinediones (diBrPDs) have
emerged as a class of disulfide-bridging reagents with great
potential as they do not require a hydrolysis step to aﬀord
serum stability and are tolerant of/compatible with common
mild reducing reagents. Modification with diBrPDs grants
good levels of homogeneity (especially with bespoke reagents),
long term blood plasma stability, and has no detectable eﬀect
on the binding capability of the parent antibody.22–25 To date,
the diBrPD linker platform has been employed extensively, e.g.
in the generation of ADCs,22,23 antibody conjugates,24,26 anti-
body-directed photosensitisers,27,28 protein–protein conju-
gates,29 and a targeted nanotherapeutic.30
However, whilst diBrPDs address some of the key remaining
issues for disulfide rebridging reagents, significant challenges
still remain in their synthesis and application. These are dis-
cussed in turn below:
(1) Synthesis of the core scaﬀold. Previously reported syn-
thetic routes towards core diBrPD scaﬀolds proceed under
harsh conditions that have excluded the use of certain func-
tional groups to be appended to the scaﬀold.31,32 These routes
require pre-formation of dibromomaleic anhydride 2 via bro-
mination of maleic anhydride 1, a dangerous reaction that
requires high temperature and high pressure. We note that
whilst dibromomaleic anhydride 2 may be purchased, it has
very limited availability with suppliers and can be prohibitively
expensive (£908 per g through Sigma Aldrich). These routes
also employ trifluoroacetic acid (TFA) deprotection of the
hydrazine, prior to dehydration, increasing costs and environ-
mental impact, and decreasing overall atom eﬃciency
(Scheme 1a).26
(2) Functionalisation of the core scaﬀold in good and consistent
yields via a general protocol. A common method for adding
functionality to functional rebridging reagents is the reaction
of an amine with an activated carboxylic acid. The resultant
amide bond shows excellent stability in vivo, and a great deal
of toxic payloads, fluorescent dyes, and imaging agents are
commercially available as amines. Previously, carboxylic acid
functionalised diBrPDs 4 have been coupled with amines
using a variety of activating reagents.22–24,26,27,30 Whilst this
demonstrates a broad scope for forming functionalised
diBrPD reagents, it is also indicative of how capricious the
reaction is; for each new amine a diﬀerent activating reagent
was employed and specific reaction conditions developed. This
precludes the use of a generalised synthetic pathway to these
useful reagents (Scheme 1a).
(3) A general protocol for homogeneous antibody conjugation
without having to use bespoke reagents. We have previously
reported a pyridazinedione-based reagent with built-in reduc-
tive capacity that is capable of both reducing and functionally
rebridging the inter-chain disulfide bonds of an antibody.26
Whilst this reagent grants antibody conjugates with unpre-
cedented homogeneity, and a desirable drug-to-antibody ratio
of 4 (DAR), the synthetic diﬃculty and poor long-term stability
of the reagent without storing in the freezer under argon
limits wide-spread adoption. Methods which allow for similar
levels of homogeneity (low levels of mis-bridged species – see
Fig. 1) and DAR without the associated synthetic diﬃculty and
oxidation instability are sought after.
Herein we report a general and novel synthetic route to
functionalised diBrPDs 10 proceeding via an isolatable acti-
Fig. 1 (a) An ideal disulﬁde bridging reaction in which interchain
disulﬁde bonds are correctly bridged. (b) Schematic representations of
the undesirable mis-bridged side-products generated with most
disulﬁde bridging reagents.
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vated ester 9, incorporating a one-pot synthesis for the for-
mation of the core scaﬀold. This procedure was utilised to
generate a small library of functional diBrPDs (Scheme 1b).
The subsequent conjugation of these reagents was then opti-
mised on the clinically relevant antibody trastuzumab, and
found to proceed with excellent and unprecedented
homogeneity.
Results and discussion
Pyridazinedione (PD) core scaﬀold synthesis
Towards the development of a one-pot synthesis of the core
diBrPD scaﬀold, initial focus was given to the in situ formation
of dibromomaleic anhydride 2 from dibromomaleic acid 6
(£18 per g through Sigma Aldrich). Dibromomaleic acid 6 has
been successfully reacted with amines for the synthesis of
dibromomaleimides; a synthetic pathway similar to the gene-
ration of diBrPDs. We proposed that this reaction was proceed-
ing via dibromomaleic anhydride 2, formed through the ring-
closing dehydration of dibromomaleic acid 6 under acid con-
ditions. This theory was explored by refluxing dibromomaleic
acid 6 in deuterated acetic acid (AcOH-D4). Following the reac-
tion using 13C NMR demonstrated almost full conversion to
dibromomaleic anhydride 2 within 30 minutes (Fig. 2).
Similarly, analysis by thin-layer chromatography (TLC) indi-
cated rapid deprotection of diethyl diboc hydrazine 11 within
10 minutes of boiling in acetic acid. A protocol was developed
in which dibromomaleic acid 6 was refluxed in acetic acid for
30 min prior to addition of diethyl diboc hydrazine 11, fol-
lowed by a further 4 hours of reflux (Scheme 2a). This pro-
duced diBrPD 12 in an 82% yield, higher than the overall yield
of 68% granted by the previously reported protocol. To explore
the importance of the preformation of dibromomaleic an-
hydride 2, the reaction was performed with all reagents added
at the start in a one-pot synthesis. A decreased yield of 65%
was observed, indicating that preformation of dibromomaleic
anhydride 2 is key to achieving high yields in this instance
(Scheme 2b). This new route reduces the complexity of the syn-
Scheme 1 (a) Current synthesis of diBrPDs 4 from maleic anhydride 1 and hydrazines 3, followed by amide coupling. (b) Proposed one-pot syn-
thesis of diBrPDs 8 from dibromomaleic acid 6 and hydrazines 7, followed by generation of an isolatable activated ester 9 to enable a general route
towards functionalised diBrPDs 10.
Fig. 2 13C NMR spectra showing formation of dibromomaleic an-
hydride 2 from dibromomaleic acid 6 in boiling deuterated acetic acid
(AcOH-D4).
Organic & Biomolecular Chemistry Paper





















































































thesis of the diBrPD scaﬀold, increases overall yield and step-
economy, decreases the number of reagents required, and
eliminates the dangerous and cumbersome bromination reac-
tion of maleic anhydride through the use of relatively cheap
and readily commercially available dibromomaleic acid 6.
Development of pyridazinedione-N-hydroxysuccinimide
activated ester
Methyl ethanoic acid diBrPD 13 has been previously employed
to generate functionalised diBrPDs through amide coupling
reactions with amines. However, the reaction has been shown
to be capricious and amine-dependent, requiring the develop-
ment of tailored conditions for each coupling reaction (see
introduction). To create a more generalised route towards func-
tionalised diBrPDs we attempted to synthesise and isolate a
reactive NHS-ester intermediate of diBrPD 14. It was hoped
this intermediate could be synthesised in large quantities,
stored for extended periods, and be used in a general protocol
towards functionalised diBrPDs. To this end, we attempted to
synthesise the NHS ester of methyl ethanoic acid diBrPD 13 by
reacting it with with DCC and NHS. Whilst this resulted in
complete consumption of starting material, isolation of the
desired species 14 was not possible under various conditions
despite multiple attempts. This may go some way to explaining
why the amide coupling reactions using methyl ethanoic acid
diBrPD 13 were so capricious. It was hypothesised that degra-
dation of the intermediate was occurring through intra-
molecular reaction of the activated species with the carbonyl
of the pyridazinedione ring (possibly via a 6-membered ring
transition state). To appraise this, we synthesised methyl pro-
pionic acid diBrPD 15, in which the acid is separated from the
ring system by a 2-carbon alkyl chain, i.e. leading to what
would be an undesirable 7-membered ring transition state.
Pleasingly, subjecting methyl propionic acid diBrPD 15 to ana-
logous NHS ester formation conditions led to the generation
of activated diBrPD 16 in a good yield (Scheme 3). We were
also pleased that we were able to synthesise methyl propionic
acid diBrPD 15 using the core scaﬀold synthesis outlined
above (see ESI Scheme S2†).
With activated diBrPD 16 in hand, we examined its propen-
sity to form amides upon reaction with a library of diverse
amines. The reactions proceeded with good to excellent yields
with amines containing hydrophobic, hydrophilic, terminal
alkyne and strained alkyne functional groups all being toler-
ated (Table 1). A secondary amine was also reactive towards
diBrPD 16 producing amide 17c in good yield; a feat not feas-
ible for reaction with methyl ethanoic acid diBrPD 13.
Moreover, synthesis of diBrPD-amide 17f proceeded with a
high yield of 78%; this contrasts starkly with the 8% yield
obtained for the same coupling reaction when using previous
methyl ethanoic acid diBrPD 13 (Table 1, Reaction F).24
These results demonstrate the utility of activated diBrPD
16, a reagent which enables a general route towards the func-
tionalisation of the core diBrPD scaﬀold. Furthermore, this
compound was found to be stable at −20 °C for at least
3 months and not prone to oxidation or intramolecular
decomposition; increasing its applicability as a building block




The monoclonal antibody trastuzumab 18, an FDA-approved
therapeutic for HER2+ breast cancers,33 was chosen as a
model to appraise and optimise the conjugation of functional
diBrPD reagents 17a–e. Trastuzumab 18 is also employed
within the clinically approved ADC Kadcyla®,9 and multiple
pre-clinical therapeutics,20,34,35 and thus was deemed an
appropriate model system. As discussed above, typical di-
sulfide bridging reagents yield some mis-bridged species in
addition to the desired fully re-bridged antibody (see introduc-
Scheme 2 (a) Synthesis of diethyl dibromo PD 12 using commercially
available dibromomaleic acid 6 (b) Synthesis of diethyl dibromo PD 12
using dibromomaleic acid 6 reﬂuxed for 1 h prior to addition of diethyl
diboc hydrazine 11.
Scheme 3 (a) Attempted synthesis of NHS-activated methyl ethanoic
acid diBrPD 14 (b) Synthesis of NHS activated methyl propionic acid
diBrPD 16.
Paper Organic & Biomolecular Chemistry





















































































tion). The only protocol that does not suﬀer from this issue
requires intricate synthesis of a complex reagent that is prone
to oxidation.26 We set out to develop a protocol using diBrPD
reagents which could minimise these undesirable mis-bridged
species without the use of complex reagents. A key objective
was to hinder formation of the mis-bridged “half antibody”
species (Fig. 1), in which the hinge disulfides become
scrambled and the bridging reagent adds across the intra-
chain cysteines rather than inter-chain. Therefore, an optimi-
sation study with these reagents to determine the best con-
ditions for obtaining high levels of homogeneity and a pyrid-
azinedione-to-antibody ratio (PDAR) of 4 was performed.
We first explored the relationship between the two reac-
tions steps, reduction and rebridging, to determine how the
order of reagent addition would aﬀect the composition of the
final product. There are 3 generally accepted functional
rebridging strategies: (1) a step-wise protocol in which
reduction is performed first, followed by removal of the redu-
cing agent and addition of the bridging reagent; (2) a sequen-
tial protocol in which reduction is followed by addition of the
bridging reagent without intermediate purification to remove
the reducing reagent; and (3) an in situ protocol in which the
bridging reagent is added before addition of the reducing
agent. Due to cross-reactivity with commonly employed redu-
cing agents, many disulfide bridging reagents require a step-
wise protocol. It has been noted previously that diBrPDs are
amenable to both sequential and in situ protocols due to a
lack of (or minimal) cross-reactivity with the commonly
employed reducing agent tris(2-carboxyethyl)phosphine
(TCEP) under the reaction conditions.26 These 3 strategies
were compared for the modification of trastuzumab 18 using
synthesised strained alkyne diBrPD 17e. This reagent was
chosen for this study due to its chemical complexity; we
wanted to appraise the platform with a chemical linker which
contained both hydrophilic and hydrophobic components, as
well as reactive functionalities.
The step-wise protocol reduction was achieved by incu-
bation of trastuzumab 18 with TCEP, followed by purification
via ultrafiltration and subsequent addition of diBrPD 17e. A
similar approach was employed for the sequential protocol but
with no purification before addition of diBrPD 17e. Finally, the
in situ protocol involved addition of diBrPD 17e prior to
addition of TCEP. In each case, 10 equivalents of reducing
agent (i.e. 2.5 eq. per disulfide) and 20 equivalents of diBrPD
17e (i.e. 4 eq. per disulfide) were employed (Fig. 3c). From the
results, it is clear to see that whilst all 3 protocols granted a
desired PDAR of 4, both the step-wise and sequential protocols
yielded significantly poorer functional rebridging; SDS-PAGE
and densitometry analysis show greater levels of half antibody
species when compared to the in situ protocol. We hypothesise
that this result is due to the relative kinetics of the two reac-
tions steps (reduction and rebridging); reduction of the di-
sulfide bond using TCEP may be slower than the subsequent
reaction of the liberated cystine residues with diBrPD 17e. The
presence of a high concentration of diBrPD 17e in situ allows
the rebridging step to occur almost immediately after
reduction whilst the antibody domains are still templated by
various intermolecular forces. Conversely, both step-wise and
sequential protocols allow enough time for some loss of the
antibody template, leading to significant mis-bridging of the
liberated cysteine residues upon addition of the bridging
reagent. This result is in accordance with the previously
reported two-in-one pyridazinedione reagent.26
We next studied the eﬀect of temperature on the bridging
eﬃciency. Based on the previous results, an in situ protocol
was utilised, with 10 equivalents of TCEP and 20 equivalents
of diBrPD 17e. Incubation over 16 hours at 4 °C, 8 °C, 25 °C
and 37 °C highlighted a significant temperature dependence
Table 1 Reaction of activated NHS-activated diBrPD 16 with a library of amines
Reaction Solvent Amine Product number Yield
A CH2Cl2 17a 78%
B CH2Cl2 17b 71%
C MeCN 17c 76%
D MeCN 17d 87%
E MeCN 17e 72%
F MeCN 17f 78%
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on the overall composition of the final construct (Fig. 3d): in
each case, a PDAR of 4 was observed, though increasing levels
of heterogeneity were observed as the temperature was
increased. This could be due to the higher temperature
increasing the rate at which the antibody loses its template
upon reduction, or by increasing the rate of TCEP reduction
itself. Regardless, these results clearly show that lower temp-
eratures are beneficial to increasing the homogeneity of the
final constructs. To the best of our knowledge the eﬀect of
temperature on the reactions of disulfide bridging reagents
has not been reported. We anticipate that this discovery will be
transferable to other reagents and thus prove useful through-
out the field in a general sense.
Finally, we looked at the eﬀect of equivalents of diBrPD 17e
on bridging eﬃciency. Employing an in situ protocol at 4 °C,
we reacted 15, 30, 40, and 50 equivalents of diBrPD 17e with
trastuzumab 18. In each case the amount of organic solvent
(DMSO) included to solubilise the linker remained constant.
These results show that increasing the equivalents of diBrPD
17e does not grant greater levels of homogeneity; in fact,
increasing the amount of diBrPD 17e beyond 30 equivalents
granted lower PDAR values (Table 2). During these reactions a
visible precipitate was observed, attributed to precipitation of
the linker, which may account for the observation. Whilst the
SDS-PAGE gels of these experiments show high homogeneity,
the corresponding low PDAR values indicate this could be
down to re-oxidation of the disulfide bridges rather than func-
tional rebridging. Gratifyingly, these results demonstrate that
as low as 15 equivalents of diBrPD 17e can be employed
without sacrificing bridging eﬃciency and the homogeneity of
the final product.
Validation of an optimised protocol
The result of the optimisation study detailed above were com-
bined to develop an optimised conjugation protocol of diBrPD
17e with trastuzumab 18. Trastuzumab 18 was mixed with 20
equivalents of diBrPD 17e and allowed to cool to 4 °C for
2 hours. After this time, 10 equivalents of TCEP were added
and the reaction incubated at 4 °C for 16 hours. Pleasingly,
this led to a construct with a PDAR of 4 and a high level of
Fig. 3 Optimisation of the disulﬁde bridging of trastuzumab using diBrPD 17e. Unless otherwise speciﬁed, a concentration of 20 μM of trastuzumab
was employed. Unless other speciﬁed, 10 equivalents of TCEP·HCl and 20 equivalents of PD 17e were employed. For full details of each protocol
refer to ESI.† (a) Schematic representation of the generation of a PDAR 4 trastuzumab conjugate. (b) SDS-PAGE gel: M: molecular weight protein
marker in kDa; N: native trastuzumab 18; 1: step-wise protocol; 2: sequential protocol; 3: in situ protocol; 4: in situ protocol 4 °C; 5: in situ protocol
8 °C; 6: in situ protocol 25 °C; 7: in situ protocol 37 °C; 8: in situ protocol 15 equivalents of diBrPD 17e; 9: in situ protocol 20 equivalents of PD 17e;
10: in situ protocol 30 equivalents of PD 17e; 11: in situ protocol 40 equivalents of diBrPD 17e; 12: in situ protocol 50 equivalents of diBrPD 17e.
(c) Densitometry traces showing the eﬀect of protocol on bridging eﬃciency: (1) step-wise; (2) sequential; (3) in situ. (d) Densitometry traces
showing the eﬀect of temperature (4 °C, 8 °C, 25 °C, and 37 °C) on bridging eﬃciency. (e) Densitometry traces showing the eﬀect of equivalents of
diBrPD 17e (15, 20, 30, 40, and 50 equivalents) on bridging eﬃciency.
Table 2 Optimisation of the disulﬁde rebridging of trastuzumab 18 with diBrPD 17e
Protocol Temperature/°C Equivalents of diBrPD x
1 2 3 4 8 25 37 15 20 30 40 50
% Half antibodya 23 20 8 3.5 4.8 14.1 18.5 6.0 4.8 4.0 0c 1.7c
PDARb 4.1 4.1 3.9 4.2 3.8 3.9 4.2 3.9 3.9 3.9 3.6 3.3
a Calculated from densitometry traces in Fig. 4 using Image J. See ESI for details. b PDAR was calculated using UV-vis spectrophotometry. See ESI
Fig. S19–S21. c Low PDAR values indicate these values may not be representative. See discussion above.
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homogeneity, with densitometry analysis indicating only 5%
of the total antibody concentration existed as the mis-bridged
half antibody. To demonstrate scope, this protocol was applied
to diBrPDs 17a–d. To our delight, in each case equally high
levels of homogeneity were observed with conjugates 19a–e
along with optimal PDARs (Fig. 4, Table 3). ELISA of conju-
gates 19a–e demonstrated no loss of antigen binding when
compared to native trastuzumab 18 (Fig. S24†), providing evi-
dence that modification with diBrPDs 17a–e does not aﬀect
antigen binding. This study confirms that the protocol is com-
patible with linkers of varying hydrophobicity and functional-
ities, an important factor for the development of ADCs (Fig. 4,
Table 3).
Conclusion
To conclude, we have developed several novel protocols to
improve both the synthesis and subsequent application of
functionalised dibromopyridazinediones, a promising class of
disulfide functional rebridging reagents. During this work we
have addressed two pressing challenges in their synthesis; the
formation of the core scaﬀold, and subsequent amine-coup-
ling reaction of this scaﬀold to enable chemical functionalisa-
tion. A one-pot synthesis of the core scaﬀold from readily avail-
able starting materials provides a safer and more eﬃcient
alternative to reported routes, whereas a novel isolable NHS-
ester intermediate enables a more general protocol for the
derivatisation of this scaﬀold with a variety of amines. The
capacity of these reagents to functionally rebridge disulfide
bonds was optimised on the humanised IgG trastuzumab, and
a protocol was developed which grants high levels of homo-
geneity (>90%) and a pyridazinedione-to-antibody ratio of 4.
Furthermore, the novel findings on the temperature of biocon-
jugation being critical to outcome could be a significant
general find to the field of bioconjugation as a whole.
Moreover, this procedure comes at minimal expense and com-
plexity when compared to previously published routes.
Therefore, it is expected that the development of these proto-
cols will vastly increase the accessibility of this exciting class of
reagents, and facilitate their use within the broader scientific
community.
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